This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY rides strong global demand and CyberKnife momentum, but order declines and backlog pressure temper the outlook.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.
Why Is Accuray (ARAY) Up 17% Since Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.
ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Accuray reports solid fiscal third-quarter results, witnessing growth in Product & Services revenues and reduced operating expenses.
Accuray (ARAY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 80% and 10.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher (TMO) Surges 8.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Thermo Fisher (TMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
Accuray (ARAY) Down 32% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
ARAY Stock Up as Q2 Earnings & Revenues Beat Estimates, Margins Up
by Zacks Equity Research
Accuray delivers solid fiscal second-quarter results, witnessing growth in Product revenues and reduced operating expenses.
Accuray (ARAY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Accuray (ARAY) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 300% and 4.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now
by Zacks Equity Research
PACB continues to deliver growth from its unique technologies amid business seasonality concerns.
GEHC Stock Gains on the Collaborated Launch of Care Innovation Hub
by Zacks Equity Research
GE HealthCare announces the launch of a Care Innovation Hub, a joint research collaboration with the University of California, San Francisco.
TMDX Stock Down Despite Responding to Misleading Short-Seller Report
by Zacks Equity Research
TransMedics addresses the misleading claims made in a short-seller report issued by Scorpion Capital.
Accuray (ARAY) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
Accuray (ARAY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
by Zacks Equity Research
WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.
Reasons to Add GE HealthCare Stock to Your Portfolio Now
by Zacks Equity Research
GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
GEHC Stock Gains on Long-Term Collaboration With Sutter Health
by Zacks Equity Research
GE HealthCare announces a seven-year strategic collaboration with Sutter Health.
Cardinal Health Stock May Gain With New Texas Distribution Center
by Zacks Equity Research
CAH announces the ongoing construction of a new distribution center in Texas, which is likely to support its at-Home Solutions business.
Intuitive Surgical Stock Surges on Q4 Preliminary Revenue Beat
by Zacks Equity Research
ISRG records significant growth in the top line, driven by higher system placements as well as improved pricing. Procedure volume remains strong.
PACB Stock Declines Despite Promising HiFi Sequencing Findings
by Zacks Equity Research
PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases.
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped
by Zacks Equity Research
PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025.
GKOS Stock Gains Following Positive Study Data on iDose Platform
by Zacks Equity Research
Glaukos' iDose TR achieves lasting IOP reduction and safety, transforming glaucoma treatment. The company is progressing well with its next-generation iDose TREX.